The HVTN 505 study, which tested a DNA prime–recombinant adenovirus type 5 vector boost vaccine regimen in people at increased risk in the U.S., failed to provide any protective effect.
Only one of five previous HIV vaccine efficacy trials has demonstrated even a modest reduction in infection risk (NEJM JW AIDS Clin Care Oct 22 2009). Now, the HIV Vaccine Trials Network has reported the results of a randomized, double-blind, placebo-controlled, phase IIb efficacy trial of a multigene, multiclade DNA prime–recombinant adenovirus type 5 vector boost vaccine in at-risk populations in the U.S.
A total of 2499 HIV-uninfected individuals (98% men; 70% white; median age, 29) were included in the analysis. All had substantial sexual risk behaviors for HIV infection, such as unprotected insertive or receptive anal intercourse.
HIV infection was diagnosed in 72 individuals during follow-up. Forty-eight of these infections occurred aft…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)